Jaguar Health Inc. [NASDAQ: JAGX] jumped around 0.18 points on Friday, while shares priced at $1.62 at the close of the session, up 12.50%. The company report on April 21, 2021 that REMINDER FROM JAGUAR HEALTH: Innovators with Jane King Webcast Interview to Take Place Friday, April 23, 2021 at 8:30 AM Eastern to Provide a Business Overview of Napo EU S.p.A., Jaguar’s New Italian Subsidiary.
Registration link for webcast interview appears below.
Jaguar Health, Inc. (NASDAQ:JAGX) (“Jaguar” or the “Company”) issued a reminder about the Innovators with Jane King interview of Lisa Conte, the Company’s founder, president, and CEO, and Josh Mailman, the lead sponsor of the Dragon special purpose acquisition company (the “Dragon SPAC”), that will air during a webcast this Friday, April 23, 2021, at 8:30 AM Eastern to provide a business overview of Napo EU S.p.A. (“Napo EU”), Jaguar’s wholly owned Italian subsidiary.
Jaguar Health Inc. stock is now 98.77% up from its year-to-date (YTD) trading value. JAGX Stock saw the intraday high of $1.74 and lowest of $1.43 per share. The company’s 52-week high price is 4.47, which means current price is +86.21% above from all time high which was touched on 01/08/21.
Compared to the average trading volume of 14.10M shares, JAGX reached a trading volume of 54101000 in the most recent trading day, which is why market watchdogs consider the stock to be active.
What do top market gurus say about Jaguar Health Inc. [JAGX]?
Rodman & Renshaw have made an estimate for Jaguar Health Inc. shares, keeping their opinion on the stock as Buy, with their previous recommendation back on July 11, 2017.
The Average True Range (ATR) for Jaguar Health Inc. is set at 0.18, with the Price to Sales ratio for JAGX stock in the period of the last 12 months amounting to 19.60. The Price to Book ratio for the last quarter was 7.04, with the Price to Cash per share for the same quarter was set at 0.07.
How has JAGX stock performed recently?
Jaguar Health Inc. [JAGX] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 24.62. With this latest performance, JAGX shares dropped by -10.99% in over the last four-week period, additionally plugging by 458.81% over the last 6 months – not to mention a rise of 268.18% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for JAGX stock in for the last two-week period is set at 46.09, with the RSI for the last a single of trading hit 50.58, and the three-weeks RSI is set at 45.17 for Jaguar Health Inc. [JAGX]. The present Moving Average for the last 50 days of trading for this stock 2.0188, while it was recorded at 1.4040 for the last single week of trading, and 1.1662 for the last 200 days.
Jaguar Health Inc. [JAGX]: Deeper insight into the fundamentals
Operating Margin for any stock indicates how profitable investing would be, and Jaguar Health Inc. [JAGX] shares currently have an operating margin of -283.93 and a Gross Margin at +65.05. Jaguar Health Inc.’s Net Margin is presently recorded at -360.25.
Return on Total Capital for JAGX is now -86.59, given the latest momentum, and Return on Invested Capital for the company is -133.52. Return on Equity for this stock declined to -179.03, with Return on Assets sitting at -85.32. When it comes to the capital structure of this company, Jaguar Health Inc. [JAGX] has a Total Debt to Total Equity ratio set at 94.23. Additionally, JAGX Total Debt to Total Capital is recorded at 48.52, with Total Debt to Total Assets ending up at 37.84. Long-Term Debt to Equity for the company is recorded at 72.21, with the Long-Term Debt to Total Capital now at 37.18.
Reflecting on the efficiency of the workforce at the company, Jaguar Health Inc. [JAGX] managed to generate an average of -$994,382 per employee. Receivables Turnover for the company is 3.00 with a Total Asset Turnover recorded at a value of 0.24.Jaguar Health Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 1.10 and a Current Ratio set at 1.30.
Earnings analysis for Jaguar Health Inc. [JAGX]
With the latest financial reports released by the company, Jaguar Health Inc. posted -0.56/share EPS, while the average EPS was predicted by analysts to be reported at -0.23/share. When compared, the two values demonstrate that the company fail the estimates by a Surprise Factor of -143.50%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for JAGX. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Jaguar Health Inc. go to 40.00%.
Insider trade positions for Jaguar Health Inc. [JAGX]
There are presently around $4 million, or 5.80% of JAGX stock, in the hands of institutional investors. The top three institutional holders of JAGX stocks are: VANGUARD GROUP INC with ownership of 1,581,583, which is approximately 5122.676% of the company’s market cap and around 10.62% of the total institutional ownership; GEODE CAPITAL MANAGEMENT, LLC, holding 427,466 shares of the stock with an approximate value of $0.69 million in JAGX stocks shares; and TWO SIGMA SECURITIES, LLC, currently with $0.15 million in JAGX stock with ownership of nearly New of the company’s market capitalization.
Positions in Jaguar Health Inc. stocks held by institutional investors increased at the end of May and at the time of the May reporting period, where 16 institutional holders increased their position in Jaguar Health Inc. [NASDAQ:JAGX] by around 2,256,084 shares. Additionally, 5 investors decreased positions by around 1,015,709 shares, while 2 investors held positions by with 910,606 shares. The mentioned changes placed institutional holdings at 2,361,187 shares, according to the latest SEC report filing. JAGX stock had 11 new institutional investments in for a total of 675,767 shares, while 4 institutional investors sold positions of 910,848 shares during the same period.